Original paper

Effectiveness and safety of tocilizumab for the treatment of refractory systemic sclerosis associated interstitial lung disease: a case series

Volume: 78, Issue: 11, Pages: e123 - e123
Published: Oct 23, 2018
Abstract
We read with great interest the results of the double-blind phase 2 faSScinate clinical trial,1 in which there was encouraging (although not statistically significant) numerical improvement in skin thickening and evidence of less decline in lung function in patients with systemic sclerosis (SSc) treated with tocilizumab (TCZ) compared with those receiving placebo. Initial investigations with TCZ in patients with SSc demonstrated improvements in...
Paper Details
Title
Effectiveness and safety of tocilizumab for the treatment of refractory systemic sclerosis associated interstitial lung disease: a case series
Published Date
Oct 23, 2018
Volume
78
Issue
11
Pages
e123 - e123
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.